FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE Drug Patent Profile

Which patents cover Fluticasone Propionate And Salmeterol Xinafoate, and when can generic versions of Fluticasone Propionate And Salmeterol Xinafoate launch?

Fluticasone Propionate And Salmeterol Xinafoate is a drug marketed by Hikma, Respirent Pharms, and Teva Pharms Usa. and is included in three NDAs.

The generic ingredient in FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE is fluticasone propionate; salmeterol xinafoate. There are twenty-nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the fluticasone propionate; salmeterol xinafoate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Fluticasone Propionate And Salmeterol Xinafoate

A generic version of FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE was approved as fluticasone propionate; salmeterol xinafoate by HIKMA on December 17^th, 2020.

Summary for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE

US Patents:	0
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	8
Clinical Trials:	43
Patent Applications:	1,118
DailyMed Link:	FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE at DailyMed

Recent Clinical Trials for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Novartis Pharmaceuticals	Phase 3
Imperial College London	Phase 4
European Research Council	Phase 4

See all FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE clinical trials

Pharmacology for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE

Drug Class	Corticosteroid beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	203433-001	Dec 17, 2020	AB	RX	No	No
Teva Pharms Usa	FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	213948-002	Dec 13, 2021	AB	RX	No	No
Respirent Pharms	FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	214464-001	Jan 12, 2026	AB	RX	No	No

EU/EMA Drug Approvals for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Teva B.V.	Airexar Spiromax	salmeterol xinafoate, fluticasone propionate	EMEA/H/C/004267Airexar Spiromax is indicated for use in adults aged 18 years and older only.AsthmaAirexar Spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist.Chronic Obstructive Pulmonary Disease (COPD)Airexar Spiromax is indicated for the symptomatic treatment of patients with COPD, with a FEV1	Withdrawn	no	no	no	2016-08-18

Market Dynamics and Financial Trajectory for Fluticasone Propionate and Salmeterol Xinafoate

Last updated: February 17, 2026

Market Overview

Fluticasone propionate combined with salmeterol xinafoate is marketed primarily as Advair (or its generic equivalents), a medication used to manage asthma and chronic obstructive pulmonary disease (COPD). It functions as a long-acting beta-agonist and inhaled corticosteroid.

The global market for combination inhalers containing these ingredients has expanded steadily, driven by increasing prevalence of respiratory diseases and advances in inhaler technology. The inhaler segment accounted for approximately $8 billion in revenue in 2022, with a compound annual growth rate (CAGR) projected at around 5% through 2027[1].

Key Market Drivers

• Rising respiratory disease burden: According to WHO, over 300 million people have asthma and 200 million suffer from COPD globally. Aging populations and pollution contribute to rising prevalence.
• Brand dominance and generics: GSK's Advair remains the dominant product. However, patent expirations and regulatory pathways are encouraging generics, expanding market access.
• Innovation and formulation advances: New inhaler devices improve drug delivery, adherence, and patient outcomes, fostering more consistent market growth.
• Regulatory environment: Implementation of high-quality standards and approvals by agencies like the FDA and EMA influence market entry and competition.

Market Challenges

• Patent expiries: Advair's patent expired in the US in 2019, allowing generic versions to enter the market, leading to price competition.
• Pricing pressures: Insurance companies and health systems increasingly negotiate drug prices, impacting margins.
• Competition from other inhaled therapies: Including combination products with different active ingredients or delivery mechanisms.
• Side effect profiles: Potential adverse events influence physician prescribing habits and patient adherence.

Financial Trajectory and Revenue Estimates

The revenue for these combined drugs has shown resilience, despite patent expirations, owing to sustained demand and generic entry.

Year	Estimated Global Market Revenue (USD billion)	Growth Rate	Notable Factors
2022	8.0	—	Dominance of Advair; patent expiry in US
2023	8.4	5%	Increased generic penetration, stabilization
2024	8.8	4.76%	Market expansion in emerging markets
2025	9.2	4.55%	New formulations and patent challenges
2026	9.7	5.43%	Product launches and increased COPD prevalence

Regional Variations

• United States: Largest market, with revenues reaching over $3.5 billion in 2022. Patent cliffs led to significant generic sales, but brand loyalty maintains steady demand.
• Europe: Growing market, especially in Germany, France, and the UK. Pricing and reimbursement policies influence sales.
• Asia-Pacific: Fastest-growing region, driven by rising asthma and COPD cases, lower drug prices, and expanding healthcare infrastructure.

Market Entry and Competition

New entrants include generic manufacturers following patent expiration, along with bioscience companies developing next-generation inhaler devices and combination therapies. The competitive landscape comprises:

• GSK (Advair producers)
• Teva Pharmaceuticals
• Mylan
• Cipla
• Sun Pharma

Generics have eroded brand-market share but face challenges due to device compatibility, formulation stability, and regulatory approvals.

R&D Focus and Pipeline

Research emphasizes:

• Improved inhaler device technology
• AI-based inhaler adherence systems
• Novel combination therapies targeting distinct pathways
• Reduced side effect profiles

This pipeline aims to extend market longevity and address unmet respiratory health needs.

Regulatory Environment

Key regulations include the FDA’s ANDA pathway for generics and EMA's approval processes. Market access hinges on demonstrated bioequivalence and safety profiles.

Summary

While Advair remains a substantial revenue generator, patent expirations have compounded generic competition, with revenues stabilizing and gradually increasing due to regional growth and pipeline innovation. Future growth hinges on device improvements, emerging markets, and new combination formulations.

---

Key Takeaways

• The global inhaler market for fluticasone propionate and salmeterol xinafoate remains robust, with a steady CAGR of approximately 5%, despite patent expirations.
• Patent expiries and increased generic competition have pressured margins but expanded access and volume sales.
• The largest revenue stems from the US, with emerging markets showing faster growth due to rising respiratory disease prevalence.
• Innovation in inhaler technology and combination therapies will shape future revenue streams.
• Regulatory pathways, regional reimbursement policies, and global disease burden will influence market trajectory.

---

FAQs

1. What is the primary driver for growth in the fluticasone propionate and salmeterol xinafoate market?
The increase in respiratory disease prevalence, particularly asthma and COPD, combined with regional expansion into emerging markets, drives growth.

2. How has patent expiry affected the product’s revenue?
Patent expiry has allowed generics to enter the market, reducing brand prices but increasing overall volume and access, leading to a stabilization of revenue.

3. Who are the main competitors in this market?
GSK dominates with Advair, while Teva, Mylan, Cipla, and Sun Pharma are significant generics players.

4. What innovations are expected to impact this market?
Advancements include inhaler device technology, adherence systems, combination therapies targeting additional pathways, and formulations with fewer side effects.

5. What regulatory factors influence market dynamics?
Bioequivalence requirements for generics, approval pathways for new formulations, and reimbursement policies significantly shape market entry and competition.

---

References

[1] MarketsandMarkets. "Inhalers Market by Product, Application, and Region – Global Forecast to 2027."